Home › Companies › GLYCOMIMETICS INC. › 2023-2024
At GLYCOMIMETICS INC.'s shareholder meeting held May 1, 2024, in the 2023-2024 proxy season, 50 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 157 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS… — GLYCOMIMETICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: GLYCOMIMETICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 2, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and GLYCOMIMETICS INC.’s Form 8-K, filed May 2, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 1, 2024: 6 items on GLYCOMIMETICS INC.’s Form 8-K, filed May 2, 2024: 4 approved · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore GLYCOMIMETICS INC. in the interactive database Compare manager voting policies
These tallies are GLYCOMIMETICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 2, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Daniel Junius | 34,583,868 | -- | -- | 2,665,886 | -- | 93% | Not verified | — |
| Elect Director: Rachel King | 37,007,330 | -- | -- | 242,424 | -- | 99.3% | Not verified | — |
| 2. The appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 | 50,319,444 | 40,448 | 121,215 | -- | -- | 99.9% | Approved | — |
| 3. The executive compensation of the Company's named executive officers as disclosed in the Proxy Statement | 35,292,808 | 1,881,276 | 75,670 | -- | -- | 95% | Approved | — |
| 4. An amendment to the Company's Amended and Restated Certificate of Incorporation (the " Restated Certificate ") to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares | 49,332,242 | 1,014,592 | 134,273 | -- | -- | 98% | Approved | — |
| 5. An amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation | 36,172,684 | 1,045,748 | 31,322 | -- | -- | 97% | Approved | — |
Source: GLYCOMIMETICS INC., Form 8-K, filed with the SEC on May 2, 2024 — read the filing on EDGAR.
Each item below shows how the 50 asset managers that disclosed a GLYCOMIMETICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Daniel Junius
GLYCOMIMETICS INC.’s own tally for this item (“Elect Director: Daniel Junius”): 34,583,868 for, 2,665,886 withheld, per its Form 8-K filed May 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 3,268,144 for, 99,222 withheld, 933 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 79,496 | Withhold |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 10,946 | Withhold |
| Dimensional | 0 | 0 | 0 | 6,080 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 2,700 | Withhold |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 933 | 0 | Abstain |
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Rachel King
GLYCOMIMETICS INC.’s own tally for this item (“Elect Director: Rachel King”): 37,007,330 for, 242,424 withheld, per its Form 8-K filed May 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 3,362,219 for, 6,080 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 79,496 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 6,080 | Withhold |
| Blackstone Alternative Investment Funds | 2,700 | 0 | 0 | 0 | For |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 933 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation.
GLYCOMIMETICS INC.’s own tally for this item (“5. An amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation”): 36,172,684 for, 1,045,748 against — passed, per its Form 8-K filed May 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 5: Stockholders approved an amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 3,368,299 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 79,496 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| Dimensional | 6,080 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,700 | 0 | 0 | 0 | For |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 933 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Restated Certificate") to increase the number of shares of common stock authorized for issuance from 100,000,000 to 150,000,000.
GLYCOMIMETICS INC.’s own tally for this item (“4. An amendment to the Company's Amended and Restated Certificate of Incorporation (the " Restated Certificate ") to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares”): 49,332,242 for, 1,014,592 against — passed, per its Form 8-K filed May 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4: Stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation (the " Restated Certificate ") to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 3,369,299 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 79,496 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| Dimensional | 6,080 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,700 | 0 | 0 | 0 | For |
| Williamson Legacy Group, LLC | 1,000 | 0 | 0 | 0 | For |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 933 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY MATERIALS.
GLYCOMIMETICS INC.’s own tally for this item (“3. The executive compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 35,292,808 for, 1,881,276 against — passed, per its Form 8-K filed May 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: Stockholders approved, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 79,496 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| Dimensional | 6,080 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,700 | 0 | 0 | 0 | For |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 933 | 0 | 0 | 0 | For |
Fund voting reports, all 11 managers: 3,368,299 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 9,544,262 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 3,000,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 976,559 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 495,247 | 0 | 0 | 0 | For |
| BlackRock | 479,664 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 182,350 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 177,427 | 0 | 0 | 0 | For |
| Renaissance | 133,350 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 123,848 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 100,000 | 0 | 0 | 0 | For |
| Point72 | 93,119 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 84,896 | 0 | 0 | 0 | For |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 65,645 | 0 | 0 | Against |
| Northern Trust | 49,006 | 0 | 0 | 0 | For |
| Two Sigma | 45,913 | 0 | 0 | 0 | For |
| LETKO, BROSSEAU & ASSOCIATES INC | 45,250 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 41,195 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 41,194 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 30,600 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| State Street | 19,168 | 0 | 0 | 0 | For |
| Vanguard | 14,312 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| American Money Management, LLC | 9,000 | 0 | 0 | 0 | For |
| Allianz | 0 | 7,887 | 0 | 0 | Against |
Institutional-manager reports, all 45 managers: 15,744,364 for, 74,225 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of GlycoMimetics, Inc. for its fiscal year ending December 31, 2024.
GLYCOMIMETICS INC.’s own tally for this item (“2. The appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024”): 50,319,444 for, 40,448 against — passed, per its Form 8-K filed May 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 3,369,299 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,675,669 | 0 | 0 | 0 | For |
| Fidelity | 438,500 | 0 | 0 | 0 | For |
| BlackRock | 119,462 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 79,496 | 0 | 0 | 0 | For |
| Charles Schwab | 22,361 | 0 | 0 | 0 | For |
| Northern Trust | 11,161 | 0 | 0 | 0 | For |
| American Century | 10,946 | 0 | 0 | 0 | For |
| Dimensional | 6,080 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,700 | 0 | 0 | 0 | For |
| Williamson Legacy Group, LLC | 1,000 | 0 | 0 | 0 | For |
| Equitable | 991 | 0 | 0 | 0 | For |
| John Hancock | 933 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 2,675,669 |
| 2 | Fidelity | 438,500 |
| 3 | BlackRock | 119,462 |
| 4 | BRIDGEWAY FUNDS INC | 79,496 |
| 5 | Charles Schwab | 22,361 |
| 6 | Northern Trust | 11,161 |
| 7 | American Century | 10,946 |
| 8 | Dimensional | 6,080 |
| 9 | Blackstone Alternative Investment Funds | 2,700 |
| 10 | Equitable | 991 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | BVF INC/IL | 9,544,262 |
| 2 | Octagon Capital Advisors LP | 3,000,000 |
| 3 | Goldman Sachs | 976,559 |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 495,247 |
| 5 | BlackRock | 479,664 |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 182,350 |
| 7 | MARSHALL WACE, LLP | 177,427 |
| 8 | Renaissance | 133,350 |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 123,848 |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 100,000 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to GLYCOMIMETICS INC. for the 2023-2024 season, so there is no denominator to divide by.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
GLYCOMIMETICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
proxyvotesnow.com, “GLYCOMIMETICS (CBIO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/glycomimetics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.